Methamphetamine-use disorder medication guidance

Methamphetamine treatment and off-label medicine discussion

Methamphetamine treatment includes behavioral care, safety review and selected off-label medication discussion when appropriate. Bupropion with naltrexone has primary-study evidence and guideline support for selected patients, while neither that combination nor another medication has an FDA-approved methamphetamine-use-disorder indication.

Review psychiatric and physical symptoms

Describe sleep loss, low mood, hallucinations, other substances and physical symptoms. The assessment determines whether outpatient care is suitable and what needs urgent treatment.

Understand the proposed off-label plan

Ask why a medicine is being considered, what outcome is being monitored and when benefit and side effects will be reviewed. Naltrexone still requires opioid safety checks and bupropion still has seizure and other contraindications. Follow the clinician’s instructions for the specific treatment rather than a research regimen.

Treatment for stimulant use disorder

Treatment for problematic cocaine, methamphetamine or prescription stimulant use begins with a safety and substance-use assessment. The plan can address cravings, mood, sleep, health complications and the situations that lead to use. There is no FDA-approved medication specifically for stimulant use disorder. Effective treatment still exists, and selected off-label medicines may be considered alongside behavioral care.

How treatment for stimulant use disorder works

Stimulants affect brain signaling related to energy, attention and reward. Repeated use can be followed by fatigue, low mood, sleep disruption and cravings. These symptoms do not prove that a particular supplement or medicine will “reset dopamine.” The clinician looks at the course of symptoms, current use and other conditions rather than assigning a fixed recovery timetable.

Eligibility: Treatment for stimulant use disorder

An evaluation is appropriate for loss of control, recurrent use despite harm, difficulty stopping or problematic use of a prescription. Taking an ADHD medicine as prescribed is not automatically stimulant use disorder. The visit should assess ADHD, depression, anxiety, psychosis, other substance use and medical risks. Chest symptoms, severe agitation, overheating, hallucinations or inability to remain safe can require emergency care.

What to expect: Treatment for stimulant use disorder

Review use and immediate health needs

Describe the substances, routes, recent pattern, sleep, nutrition and any chest or neurological symptoms. Include possible fentanyl exposure, alcohol and sedatives. Testing and examination may be needed depending on the history. An unstable medical or psychiatric condition takes priority over routine craving treatment.

Discuss evidence-based behavioral treatment

Contingency management is a primary recommended treatment component: a structured program uses agreed incentives to reinforce goals such as attendance or verified abstinence. Cognitive behavioral therapy and community reinforcement can help with triggers, coping and daily routines. Ask whether these treatments are actually offered or require referral; general counseling is not automatically a contingency-management program.

Consider medication when it fits

A clinician may consider selected off-label options based on the stimulant, severity and co-occurring conditions. Bupropion with naltrexone is one studied option for methamphetamine use disorder, but it is not FDA-approved for that disorder and does not help everyone. Medication selection must also account for opioid exposure, seizures, liver health and other contraindications.

Build a realistic follow-up plan

Discuss sleep, food, daily structure, work pressures and people or settings associated with use. Identify a response to a strong urge and a route back to care after a lapse. Follow-up should review symptoms and functioning, not only whether a test is positive. Persistent fatigue or mood symptoms may need reassessment.

Preparing for your appointment

Bring prescriptions, previous treatment records and details of recent use. Explain whether the stimulant was obtained by prescription and how use changed. Tell the clinician about other medicines, prior seizures, cardiac disease and pain treatment. If psychiatric medicines are already prescribed, identify the clinician so care can be coordinated. Do not stop prescribed ADHD or mood treatment solely because you are seeking an addiction assessment.

Risks and when to seek help

Call 911 for chest pain, stroke-like symptoms, seizure, severe overheating, collapse or dangerous confusion. New or severe psychosis, suicidal symptoms or inability to stay safe needs urgent assessment. Fentanyl may be present in a stimulant supply; have naloxone and an emergency plan for possible opioid overdose. Naloxone does not treat stimulant toxicity itself, so emergency care remains essential.

Follow-up and treatment review

Track cravings, use, sleep, energy and mood without treating a lapse as a reason to disappear from care. If an off-label medicine is used, review benefit and side effects at an agreed time and confirm how it will be stopped or changed if ineffective. A primary trial result is not a personal success prediction. Behavioral and recovery support remain part of the plan when medication is considered.

Appointments, costs and coverage

Ask which behavioral treatments, medication evaluations and referrals the service provides. Confirm visit frequency, testing costs and who manages co-occurring psychiatric care. Any proposed prescription or off-label combination depends on your assessment and treatment goals. If intensive or residential care is recommended, clarify why and how the referral works.

Medical sources

• ASAM/AAAP stimulant use disorder guideline
• ASAM/AAAP clinical practice guideline on stimulant use disorder
• Trivedi et al.: bupropion and naltrexone in methamphetamine use disorder
• CDC: five things to know about naloxone
• SAMHSA: co-occurring disorders and other health conditions
• VIVITROL: prescribing information
• DailyMed: smoking-cessation bupropion SR label
• DailyMed: acamprosate delayed-release tablets
• DailyMed: disulfiram tablets
• DailyMed: varenicline tablets and starter kit
• SAMHSA: cannabis use disorder in primary care, lifespan approach
• DEA: Methamphetamine fact sheet
• Treatment and Recovery | National Institute on Drug Abuse (NIDA)